C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2

被引：0
|
作者：
Dubinsky, Marla C.
Hudesman, David
Steinwurz, Flavio
Kulisek, Nicole
Salese, Leonardo
Paulissen, Jerome
Su, Chinyu
de Leon, Dario Ponce
Magro, Fernando
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1870
引用
收藏
页码：S1196 / S1197
页数：2
相关论文
共 10 条
  • [1] CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2
    Dubinsky, M. C.
    Hudesman, D. P.
    Steinwurz, F.
    Kulisek, N.
    Salese, L.
    Paulissen, J.
    Su, C.
    Ponce de Leon, D.
    Magro, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S346 - S347
  • [2] Fecal Calprotectin Levels, C-Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study
    Dubinsky, Marla C.
    Hudesman, David P.
    Kulisek, Nicole
    Salese, Leonardo
    Paulissen, Jerome
    Su, Chinyu
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S474 - S475
  • [3] Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
    Dubinsky, Marla C.
    Magro, Fernando
    Steinwurz, Flavio
    Hudesman, David P.
    Kinnucan, Jami A.
    Ungaro, Ryan C.
    Neurath, Markus F.
    Kulisek, Nicole
    Paulissen, Jerome
    Su, Chinyu
    de Leon, Dario Ponce
    Regueiro, Miguel
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (01) : 51 - 61
  • [4] The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
    Panaccione, R.
    Sapin, C.
    Chan-Diehl, F. W.
    Moses, R. E.
    Siegmund, B.
    Walsh, A.
    Kobayashi, T.
    Parambir, D. S.
    Travis, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I167 - I168
  • [5] ACHIEVEMENT OF CLINICAL AND ENDOSCOPIC OUTCOMES BY BASELINE CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RECEIVED RISANKIZUMAB INDUCTION TREATMENT: A POST-HOC ANALYSIS OF THE INSPIRE STUDY
    Bossuyt, Peter
    Louis, Edouard
    Gecse, Krisztina
    Abreu, Maria T.
    Gionchetti, Paolo
    Rubin, David T.
    Marced, Elena
    Gonzalez, Yuri Sanchez
    Hecht, Patrick
    Kalabic, Jasmina
    Vladea, Ramona C.
    Zhang, Yafei
    Reinisch, Walter
    GASTROENTEROLOGY, 2024, 166 (05) : S806 - S807
  • [6] Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
    Sands, Bruce E.
    Dubinsky, Marla C.
    Kotze, Paulo G.
    Vermeire, Severine
    Panaccione, Remo
    Long, Millie D.
    Woolcott, John C.
    Wu, Joseph
    Mcdonnell, Aoibhinn
    Goetsch, Martina
    Bananis, Eustratios
    Yarur, Andres J.
    INFLAMMATORY BOWEL DISEASES, 2025,
  • [7] Decrease in fecal calprotectin and C-reactive protein levels correlate with improved clinical outcomes in patients with moderately to severely active Crohn's disease treated with mirikizumab
    Charabaty, A.
    Kayal, M.
    Kelly, C. R.
    Cohen, B. L.
    D'Haens, G.
    Hart, A.
    Chan-Diehl, F.
    Yu, G.
    Brogan, Y.
    Protic, M.
    Moses, R.
    Fisher, D.
    Travis, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1628 - i1630
  • [8] Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC
    Peyrin-Biroulet, L.
    Yen, M.
    Zhou, W.
    Dong, B.
    Danese, S.
    Feagan, B. G.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1997 - i1998
  • [9] Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial
    Yarur, Andres J.
    Chiorean, Michael, V
    Panes, Julian
    Jairath, Vipul
    Zhang, Jinkun
    Rabbat, Christopher J.
    Sandborn, William J.
    Vermeire, Severine
    Peyrin-Biroulet, Laurent
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (06): : 885 - 894
  • [10] Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
    Panes, J.
    Loftus, E. V., Jr.
    Armuzzi, A.
    Siegmund, B.
    Sands, B. E.
    Boland, B. S.
    Kalabic, J.
    Lai, J. H.
    Sharma, D.
    Remple, V.
    Gonzalez, Y. Sanchez
    Lindsay, J. O.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1585 - I1586
1